市场调查报告书
商品编码
1546284
心电图扫描器(ECG)的全球市场的评估:各类型,各技术,各导线类型,各终端用户,各地区,机会,预测(2017年~2031年)Electrocardiograph (ECG) Market Assessment, By Type, By Technology, By Lead Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球心电图机 (ECG) 市场规模预计将从 2023 年的 84.019 亿美元增至 2031 年的 152.3169 亿美元,复合年增长率预计为 7.72%。由于心臟病的增加,该市场正在稳步增长,预计未来将继续大幅增长。
心电图机是一种用于记录心跳并分析可能的心血管问题的设备和技术。随着心血管疾病负担的增加,对心电图检查和新设备的需求也增加。心电图设备市场预计将在设计和功能方面的技术进步、人工智慧和设备学习的整合以及用于心电图记录的可穿戴设备的成长趋势等因素的影响下成长。政府透过提供足够的医疗设备来加强医疗基础设施的努力正在推动市场的成长。此外,不断增加的投资和将技术整合到心电图设备中的新兴新创公司正在推动市场成长。
例如,2024 年 4 月,班加罗尔健康科技新创公司 Tricog Health India Pvt Ltd. 在 B2 轮融资中筹集了 850 万美元,投资者包括 OMRON Healthcare India Pvt Ltd. 和 Sony Innovation Fund I。该公司利用人工智慧分析心电图/心电图和迴声扫描来诊断心臟异常,这笔资金将进一步开发利用人工智慧的心臟护理解决方案。然而,儘管存在多种驱动因素??,但诸如大量本地参与者的市场饱和以及各国不同的严格监管程序等挑战是市场成长的主要障碍。
心血管疾病盛行率增加
全世界心血管疾病负担的增加是心电图设备和相关诊断技术需求和采用增加的主要驱动力,这些设备和技术能够实现这些疾病的早期检测和管理。由于心血管疾病主要透过心电图技术诊断,心血管疾病负担的增加将增加对心电图设备和服务的需求。致力于心血管健康的各种组织,包括美国心臟协会、英国心臟基金会和世界卫生组织,一致报告心血管疾病显着增加。例如,2024 年 6 月,两项新的美国心臟协会主席建议报告预测,超过 1.84 亿人(占美国人口的 61% 以上)将患有某种形式的心血管疾病 (CVD) 和总 CVD。 2050 年,相关成本预计将增加两倍,达到1.8 兆美元。
科技进步推动市场成长
与医疗技术的其他领域一样,心电图设备也显示出多项技术进步。最近的技术进步包括穿戴式心电图设备(例如美国 FDA 批准的 Apple Watch Series 4)、人工智慧辅助心电图解读、便携式心电图监视器、非接触式监护系统、基于云端的系统以及与远距医疗的整合。这些进步旨在提高心臟病的诊断准确性并提高数据收集和分析的效率。人工智慧与心电图的整合预计将带来巨大的改进,并使患者更容易获得心电图服务,从而带来后续的市场扩张。例如,2024 年 5 月,OMRON Healthcare India Pvt Ltd 宣布与 AliveCor India(AliveCor 的子公司)建立合作伙伴关係。透过此次合作,除了血压监测产品外,欧姆龙还将提供基于人工智慧的手持式便携式心电图技术。该合作伙伴关係将创建一种可以检测包括心房颤动在内的各种心律不整的设备,并提供心血管疾病的早期检测和管理。该协议旨在提高人们的认识并预防心血管健康,特别是在印度等高血压和心电图监测方面差异很大的国家。
本报告提供全球心电图扫描器(ECG)市场相关调查分析,提供市场规模与预测,市场动态,主要企业的形势及预测等资讯。
Global electrocardiograph (ECG) market is projected to witness a CAGR of 7.72% during the forecast period 2024-2031, growing from USD 8401.90 million in 2023 to USD 15231.69 million in 2031. The market for ECG devices is rising consistently due to increasing cardiac diseases and is anticipated to keep growing at a significant rate.
An electrocardiograph is a device and technique used to record the heartbeat and analyze any possible cardiovascular disorder. As the burden of cardiovascular diseases increases, the demand for more ECG procedures and new devices subsequently rises. The market for ECG devices is anticipated to thrive under the influence of factors like technical advancements in design and functions, integration of artificial intelligence (AI) and machine learning, the growing trend of wearable devices for recording ECG, etc. The government initiatives to strengthen the healthcare infrastructure by establishing an adequate number of medical devices drive the growth in the market. Additionally, rising investments and emerging startups integrating technology in ECG devices are boosting the market growth.
For instance, in April 2024, Tricog Health India Pvt Ltd., a Bengaluru-based health tech startup, raised USD 8.5 million in a Series B2 funding round from investors including OMRON Healthcare India Pvt Ltd and Sony Innovation Fund. The company uses AI to analyze ECG/EKG and ECHO scans to diagnose heart anomalies, and the new funding will help it further develop its AI-powered cardiac care solutions. However, despite several driving forces, challenges like saturation in the market due to the large number of local players, and stringent regulatory procedures varying from country to country pose significant hindrances to market growth.
Rising Prevalence of Cardiovascular Diseases
The rising burden of cardiovascular diseases globally is a key factor fueling increased demand and adoption of ECG machines and related diagnostic technologies to enable earlier detection and management of these conditions. Cardiovascular diseases are mainly diagnosed with ECG technology, which implies that an increase in cardiovascular disease burden will enhance the demand for ECG devices and services. Various associations working for cardiovascular health, such as the American Heart Association, the British Heart Foundation, and WHO, are consistently reporting a significant rise in cardiac diseases. For instance, in June 2024, as per the projections reported in two new American Heart Association presidential advisories, more than 184 million people, exceeding 61% of the U.S. population, are likely to have some type of cardiovascular disease (CVD) and total CVD-related costs are expected to triple to USD 1.8 trillion by 2050.
Technological Advancements Drive Market Growth
Aligning with other domains of medical technology, ECG devices are also undergoing several technical advancements. Some of the recent technical advancements include wearable ECG devices (for example, U.S. FDA-approved Apple Watch Series 4), AI-assisted ECG interpretation, portable ECG monitors, contactless monitoring systems, cloud-based systems, integration with telemedicine, and many more. These advances aim to improve accuracy in the diagnosis of heart conditions and enhance the efficiency of data collection and analysis. AI integration in ECG is anticipated to result in drastic improvements, leading to easy patient access to ECG services and subsequent market expansion. For instance, in May 2024, OMRON Healthcare India Pvt Ltd announced a collaboration with AliveCor India (a subsidiary of AliveCor, Inc.). Through this partnership, OMRON will now offer AI-based handheld portable ECG technology in addition to its blood pressure monitoring products. The collaboration will result in devices that can detect various heart arrhythmias, including atrial fibrillation, and provide early cardiovascular disease detection and management. The deal aims to enhance cardiovascular health awareness and prevent incidents, especially in a country like India, where hypertension and ECG monitoring gaps are significant.
Devices Segment Dominates the Global (ECG) Market
ECG device installations are increasing with the expanding healthcare infrastructure. With the rising burden of cardiac diseases and subsequent demand for more ECG procedures and devices, the ECG device segment is anticipated to cover a major market share. Technical advancements and device upgrades in diagnostic centers and hospitals further catalyze the increasing market share of the devices segment. For example, in January 2024, Wellysis Corp. launched its revolutionary electrocardiogram (ECG) monitoring solution, 'S-Patch,' into the lucrative United States and Indian markets. The company has secured a strategic supply agreement with a leading provider of ECG services in the United States, initially deploying 1,000 devices across Texas, Arizona, and Louisiana, with a two-year supply commitment. Additionally, Wellysis has partnered with Turtle Shell Technologies Private Limited (Dozee), a prominent bed monitoring solutions provider in India, to integrate and supply 50,000 S-Patch devices to hospital beds starting in January.
North America Dominates Electrocardiograph (ECG) Market Share
North America is anticipated to dominate the ECG market. North America, particularly the United States, has a significant demand for ECG devices due to several key factors. The high prevalence of cardiovascular diseases, an aging population, and a well-developed healthcare infrastructure with robust reimbursement policies have all contributed to this demand. Sustained efforts by healthcare organizations like the U.S. FDA to raise awareness about heart health and product approvals are also driving the demand for these diagnostic and monitoring tools in North America. For instance, in June 2024, Tempus AI, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-AF device, an AI-based algorithm designed to identify patients at increased risk of atrial fibrillation (AF). This innovative technology uses machine learning to analyze 12-lead electrocardiogram (ECG) recordings, helping clinicians detect signs of AF within the next 12 months. The device is intended for use on resting ECG recordings from patients aged 65 and older without a known history of AF.
Future Market Scenario (2024-2031F)
ECG technology plays a pivotal role in the cardiology domain, and with growing advancements, the machinery for recording ECG has changed drastically in recent years. The evolving trend of wearable devices has greatly impacted ECG monitoring as well. Nowadays, several smartwatches and other kinds of wearable devices are available in the market that can easily record patients' ECGs. This is anticipated to revolutionize the ECG market in upcoming years. Market players are also actively developing wearable devices to cater to the rising demand. For instance, in September 2023, iRhythm Technologies, Inc. launched its next-generation Zio monitor. This prescription-only ECG monitoring device is part of the company's Zio long-term continuous monitoring (LTCM) service. The new Zio monitor is 23% thinner, 62% lighter, and 72% smaller than its predecessor, enhancing patient comfort and adherence. It features a waterproof design and requires no device or adhesive manipulation during the 14-day wear period.
Key Players Landscape and Outlook
GE HealthCare Technologies, Inc., Koninklijke Philips N.V., Hill-Rom Holdings, Inc., NIHON KOHDEN CORPORATION, Fukuda Denshi Co Ltd, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Schiller AG, Spacelabs Healthcare, Inc., BPL MEDICAL TECHNOLOGIES PRIVATE LIMITED, Allengers Medical Systems Ltd are some of the leading players in the ECG market. The market witnessed some substantial market deals like mergers and collaborations to expand the market share of key players.
In February 2024, Thyrocare Technologies Ltd., a leading diagnostic service provider, acquired Chennai-based Think Health Diagnostics Pvt Ltd to expand its presence in the pre-policy medical check-up segment for the insurance market by offering both blood tests and ECGs as a one-stop solution, leveraging Think Health's operational presence in 10 cities and Thyrocare's network of over 900 blood collection phlebotomists trained to provide ECGs at home, aiming to expand these services to more than 100 cities in the next year and deliver seamless healthcare directly to patient's doorsteps.
In May 2024, WearLinq, Inc. acquired AMI Cardiac Monitoring LLC, which is an independent diagnostic testing facility with over 33 years of expertise in ambulatory cardiac monitoring. This strategic acquisition will expand WearLinq's clinical services across all 50 U.S. states and provide more patients access to its FDA-cleared 6-lead wearable ECG monitor, the eWave. The combined capabilities of AMI's clinical expertise and WearLinq's advanced technology are expected to revolutionize the field of ambulatory cardiac monitoring, enabling more accurate diagnoses and improved patient outcomes.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.